Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer

Recruiting phase 2 trial using circulating tumor DNA to risk-adapt postoperative therapy for HPV-associated oropharyngeal cancer (planned n=50).

Zachary Zumsteg